01:37 PM EDT, 03/27/2025 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.

Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.

Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.

The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.

BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including severe rheumatoid arthritis and active psoriatic arthritis, Bio-Thera said.